HTG Molecular Diagnostics enters collaboration with Bristol-Myers

HTG Molecular Diagnostics Inc. (Nasdaq: HTGM) entered a research collaboration with Bristol-Myers Squibb Co. (NYSE: BMY) to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types. Shares of HTG Molecular Diagnostics soared 56 cents to close at $2.97 while Bristol-Myers stock slipped 10 cents to close at $71.18.